Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study – Reuters
|Pfizer and BioNTech’s jointly developed COVID-19 vaccine was successful in neutralizing a new variant of the coronavirus spreading rapidly in Brazil, Reuters reports, citing the findings of a study conducted by scientists from the companies and the University of Texas Medical Branch.
Key takeaways
“Blood taken from people who had been given the vaccine neutralized an engineered version of the virus that contained the same mutations carried on the spike portion of the highly contagious P.1 variant first identified in Brazil.”
“The neutralizing ability was roughly equivalent to the vaccine’s effect on a previous less contagious version of the virus from last year.”
Previously, Pfizer has said it believes its current vaccine is highly likely to still protect against the South African variant.
Market implications
Encouraging vaccine news combined with the retreat in the US Treasury yields if boding well for the risk sentiment, as the Asian equities attempt a bounce while the S&P 500 futures extend gains towards 3,850.
The US dollar index takes a breather, easing off four-month tops at 92.50.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.